Related Experiment Video
Updated: Mar 14, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Diabetes mellitus, metformin and head and neck cancer
Rejane Augusta de Oliveira Figueiredo1, Elisabete Weiderpass2, Eloiza Helena Tajara3
1Faculdade de Saude Publica, Departamento de Epidemiologia, Universidade de Sao Paulo, Av. Dr Arnaldo, 715, 01246-904 Sao Paulo, SP, Brazil; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12, SE-171 77 Stockholm, Sweden.
Introduction:
Diabetes mellitus (DM (Diabetes Mellitus)) is directly associated with some cancers. However, studies on the association between diabetes mellitus and head and neck cancer (HNC (Head and Neck Cancer)) have rendered controversial results. The objective of this study was to evaluate the association between DM and HNC, as well as the impact of metformin use on the risk of HNC.
Material And Methods:
This case-control study was conducted within the framework of the Brazilian Head and Neck Genome Project in 2011-2014. The study included 1021 HNC cases with histologically confirmed squamous cell carcinoma of the head and neck admitted to five large hospitals in São Paulo state. A total of 1063 controls were selected in the same hospitals. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using unconditional logistic regression.
Results:
Diabetic participants had a decreased risk of HNC (OR=0.68; 95% CI: 0.49-0.95) than non-diabetic participants, and this risk was further decreased among diabetic metformin users (OR=0.54; 95% CI: 0.29-0.99). Diabetic metformin users that were current smokers (OR=0.13; 95% CI: 0.04-0.44) or had an alcohol consumption of >40g/day (OR=0.31; 95% CI: 0.11-0.88) had lower risk of HNC than equivalent non-diabetic participants.
Conclusion:
The risk of HNC was decreased among diabetic participants; metformin use may at least partially explain this inverse association.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Sulfonylureas
Psychoneuroimmunology: Diabetes and Cancer

